The recent agreement between UK diagnostics company Enigma Diagnostics and GlaxoSmithKline to commercialise a rapid point-of-care test for different strains of influenza is the latest in a series of deals that underline the growing importance of so-called companion diagnostics. It is now widely ...
Please Login to read the full article.
